Nirvana Life Sciences Inc. announce it has acquired an exclusive license for the psychedelics sector for a novel delivery system for its psychedelic based therapies currently in development. Nirvana Life Sciences Inc. has recently added a novel delivery system for active pharmaceutical ingredients (APIs) with high bioavailability and rapid onset to its portfolio. This novel delivery system, invented by the Company's Head of Innovation, Robert August for the licensor Hai Beverages Inc. will be used as a formulating agent for both water soluble and non-water-soluble APIs, whose onset when taken orally would be a standard twenty to forty-five minutes.

This delivery system will allow the compound to bypass first pass liver metabolism and directly enter the bloodstream, resulting in a rapid onset of 5 minutes or less. This delivery system also functions as a solubilizing agent for non-water-soluble materials. With the growing interest in psychedelic assisted therapy, improved ways of efficiently delivering the APIs are in demand for a range of psychedelics.

This formulating delivery system can take a psychedelic psychoactive like MDMA, which has a high rate of come up anxiety with patients and eliminate that anxiety by drastically shortening the time of onset. Also, with dissociative drugs like Ketamine, a dose could be rendered orally, but effectively come on as if injected intramuscularly, an advancement that could be revolutionary to the field of medicine.